Gates Foundation and UK Government join CARB-X

The Bill & Melinda Gates Foundation and the UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) have joined the CARB-X partnership, which supports global scientific research to develop new vaccines, preventatives and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.

The UK Government is committing up to £20 million (US$27 million), and the Bill & Melinda Gates Foundation up to US$25 million (£19 million), to CARB-X over the next three years. Combined with existing funding commitments from the Wellcome Trust and the US Government (BARDA and NIAID), CARB-X now has more than US$500 million (£375 million) to invest in antibacterial development.

CARB-X is the world’s leading non-profit partnership focused on accelerating the early development of antibiotics, vaccines, diagnostics and other products needed to save lives and to address the rising threat of superbugs. There are currently 33 projects in the CARB-X portfolio from seven countries.